Edoc Acquisition Corp. (NASDAQ:ADOC) announced this afternoon that it has mutually terminated its combination with biotechnology firm Calidi Biotherapeutics, Inc.
This morning, Edoc filed an 8-K notifying shareholders that it had postponed its scheduled extension vote from 10AM to 8PM this evening. However, the deal was subsequently terminated ahead of that meeting with Edoc also stating they intend to keep searching for a new business combination target.
Nonetheless, Edoc and Calidi are keeping the door slightly open stating that they both “may continue to discuss the possibility of engaging in a business combination, but there can be no assurance that those discussions will result in a transaction.”
Edoc will still hold its extension vote this evening to move its completion deadline to February 12, 2023. That would give Edoc an additional 6 months to search and announce a new combination agreement. However, its original trust value of $91.5 million had previously been whittled down to approximately $27.5 million at its last extension vote held on February 9.
Edoc announced its business combination agreement with Calidi on February 2, 2022, at an enterprise value of $449 million. La Jolla, California-based Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that delivers oncolytic viruses for targeted therapy against difficult-to-treat cancers.
Terms Tracker for the Week Ending January 17, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We may be heading into a Polar Vortex, but SPACs managed to generate some heat this week with three more IPOs. For those keeping count,...
Giving internet users a place to chat or post pictures of their lunch has never been an especially profitable endeavor until social media platforms gain the scale to leverage user data en masse like Meta (NASDAQ:META). But, the addition of retail investor appetites to the equation has suddenly turned even smaller platforms into a tantalizing...
At the SPAC of Dawn This week comes to a close with the debut of the year’s fourth SPAC IPO as Hennessy Capital Investment Corp. VII (NASDAQ:HVIIU) priced last night. This brings the month’s total IPO proceeds to $597.5 million, which is already a drastic year-on-year improvement from January 2023, which saw just $144 million...
Hennessy Capital Investment Corp. VII (NASDAQ:HVIIU) announced the pricing of its $175 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “HVIIU”, Friday, January 17, 2025. The new SPAC intends to seek out a business combination with a company in the industrial technology and energy transition sectors. Hennessy...
Equites and crytpo trading platform eToro has reportedly filed for a traditional IPO two-and-half years after nixing its SPAC combination and its renewed thrust to the public markets could provide a useful demonstration of where things sit for SPACs in 2025. For one, eToro is reportedly making its IPO move at a valuation of $5...